Schwabe   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Leipzig Germany (1866)
Status: No NME R&D (1866)

Organization Overview

First Clinical Trial
2005
NCT00672607
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Dr. Willmar Schwabe GmbH & Co. KG

Active Ingredients

Drugs in Phase 4 Trials (1)

rhodiola (1 trial)

Drugs in Phase 3 Trials (1)

pelargonium (1 trial)

Drugs in Phase 2 Trials (2)

gingko biloba (1 trial)

vitex agnus castus extract (1 trial)

Drugs in Phase 1 Trials (1)

ws 1442 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebrovascular Disorders (Phase 2)

Cognitive Dysfunction (Phase 2)

Common Cold (Phase 3)

Overweight (Phase 1)

Premenstrual Syndrome (Phase 2)

Stress, Psychological (Phase 4)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 5